First Axl inhibitor enters clinical trials
- 10 September 2013
- journal article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 31 (9), 775-776
- https://doi.org/10.1038/nbt0913-775a
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancerProceedings of the National Academy of Sciences of the United States of America, 2013
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patientsBiochemical and Biophysical Research Communications, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repairNature Genetics, 2012
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast CancerCancer Research, 2010
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2009
- Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma MultiformeClinical Cancer Research, 2008
- TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune ResponseCell, 2007